{
    "body": "Which is the most widely used anti-TNF drug?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21881980", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18420660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22379032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19854715", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21177290"
    ], 
    "ideal_answer": [
        "Etanercept is the most widely used anti-TNF drug."
    ], 
    "exact_answer": [
        "Etanercept"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000894", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023201", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044966", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053199", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016756"
    ], 
    "type": "factoid", 
    "id": "512d0e635274a5fb07000005", 
    "snippets": [
        {
            "offsetInBeginSection": 128, 
            "offsetInEndSection": 249, 
            "text": "higher rates are observed with anti-TNF Abs (e.g., infliximab) as compared with TNF receptor fusion protein (etanercept).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22379032", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 140, 
            "offsetInEndSection": 201, 
            "text": "Two of them received etanercept and the remainder adalimumab.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881980", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 542, 
            "offsetInEndSection": 661, 
            "text": "45 cases were collected of non-TB OIs in 43 patients receiving infliximab (n=29), adalimumab (n=10) or etanercept (n=4)", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177290", 
            "endSection": "sections.0"
        }
    ]
}